Recent Updates
Recently added Catalysts
IRIX Positive Sentiment Score: 65/100

Iridex to Report Third Quarter Financial Results on November 14, 2023

Thursday, October 26, 2023 1 min read
Key Takeaway: Iridex Corporation, a leading provider of ophthalmic laser-based medical products, has announced that it will release its third quarter financial results on November 14, 2023. The company's proprietary MicroPulse technology is noted for its efficacy in treating glaucoma and diabetic macular edema. Iridex markets its products both domestically and internationally across over 100 countries. The announcement could provide insights into the company’s financial health and business performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Iridex is a leader in innovative ophthalmic laser-based medical products.
  • The upcoming financial results may indicate positive growth and performance.
  • Iridex's technology offers effective treatments for significant eye conditions.

Full Press Release Details

MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 14, 2023.
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact:
investors@iridex.com

Frequently Asked Questions

When will Iridex release its Q3 2023 financial results?

Iridex will announce its Q3 2023 financial results on November 14, 2023.

What technologies does Iridex specialize in?

Iridex specializes in ophthalmic laser-based medical products for eye treatments.

What conditions do Iridex products treat?

Iridex products are used for glaucoma, diabetic macular edema, and other retinal diseases.

How does Iridex distribute its products?

Iridex sells products directly in the U.S. and through distributors in over 100 countries.

Tags: IRIX Viatris Investor Conferences Healthcare Iridex ophthalmic products financial results MicroPulse technology
Last updated: Oct 26, 2023